These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pharmacology of mesoionic oxatriazole derivatives in blood, cardiovascular and respiratory systems.
    Author: Corell T, Pedersen SB, Lissau B, Moilanen E, Metsä-Ketelä T, Kankaanranta H, Vuorinen P, Vapaatalo H, Rydell E, Andersson R.
    Journal: Pol J Pharmacol; 1994; 46(6):553-66. PubMed ID: 7542520.
    Abstract:
    Mesoionic oxatriazole derivatives were synthetized by GEA LTD1. The GEA compounds (GEAC) constitute a new class of NO-donors, some of which stimulate selectively guanylate cyclase abiding either platelets or leukocytes or lung tissues. In consequence, some of GEAC are potent anti-platelet, fibrinolytic, thrombolytic or broncholytic agents, both in vitro and in vivo. GEAC synergize with prostacyclin in their thrombolytic actions. They also suppress the release of histamine and leukotriene B4, and prevent degranulation of granulocytes. Methylene blue reduces, and zaprinast augments their pharmacological effects. It is suggested that within a series of the newly synthetized GEA compounds there are likely to be found potential candidates for treating either thrombotic or asthmatic disorders.
    [Abstract] [Full Text] [Related] [New Search]